beatandraise : Equity Research with AI and ChatGPT on SEC Edgar

beatandraise.com

2.2.0.7 true Collaborations (Details) (USD $) 0617 - Disclosure - Collaborations (Details) true false In Millions false false 1 USD true false false false RITUXAN [Member] biib_ProductsAxis xbrldi http://xbrl.org/2006/xbrldi biib_RITUXANMember biib_ProductsAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 $ 1 RITUXAN [Member] 0 na true na na No definition available. false true false false false false false false false false false http://biogenidec.com/role/collaborationsdetails false 1 false false false false 0 0 false false false false 1 USD true false false false RITUXAN [Member] biib_ProductsAxis xbrldi http://xbrl.org/2006/xbrldi biib_RITUXANMember biib_ProductsAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 $ na No definition available. No authoritative reference available. false 12 Collaborations (Textuals) [Abstract] 2 biib_CollaborationsTextualsAbstract biib false na duration Collaborations Textuals Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Collaborations Textuals Abstract. false 18 Percentage of Co promotion Operating Profits first fifty million, prior to October 2010 amendment 2 biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillionPriorToAmendment biib false na instant Percentage of Co promotion Operating Profits first fifty million, prior to October 2010 amendment. false false false false false false false false false false false verboselabel false 1 false true false false 0.3 0.3 false false false us-types:percentItemType pure Percentage of Co promotion Operating Profits first fifty million, prior to October 2010 amendment. No authoritative reference available. false 19 Copromotion operating profit threshold for RITUXAN in the US and Canada, to determine share of copromotion operating profit, prior to October 2010 amendment 2 biib_CoPromotionOperatingProfitThresholdForRituxanInUSAndCanadaToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment biib false credit instant Copromotion operating profit threshold for RITUXAN in the US and Canada, to determine share of copromotion operating profit,... false false false false false false false false false false false verboselabel false 1 true true false false 50000000 50.0 false false false xbrli:monetaryItemType monetary Copromotion operating profit threshold for RITUXAN in the US and Canada, to determine share of copromotion operating profit, prior to October 2010 amendment. No authoritative reference available. false 20 Percentage of share of copromotion profits exceeding $50 million, prior to October 2010 amendment 2 biib_PercentageOfShareOfCoPromotionProfitsExceedingFiftyMillionPriorToAmendment biib false na instant Percentage of share of copromotion profits exceeding $50 million, prior to October 2010 amendment. false false false false false false false false false false false verboselabel false 1 false true false false 0.4 0.4 false false false xbrli:pureItemType pure Percentage of share of copromotion profits exceeding $50 million, prior to October 2010 amendment. No authoritative reference available. false 21 Threshold of gross sales of GA 101 to be achieved in preceding 12 consecutive months under option one 2 biib_ThresholdOfGrossSalesOfGA101ToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne biib false credit duration Threshold of gross sales of GA 101 to be achieved in preceding 12 consecutive months under option one. false false false false false false false false false false false verboselabel false 1 false true false false 150000000 150.0 false false false xbrli:monetaryItemType monetary Threshold of gross sales of GA 101 to be achieved in preceding 12 consecutive months under option one. No authoritative reference available. false 22 Threshold of gross sales of GA 101 to be achieved in any 12 consecutive months under option one 2 biib_ThresholdOfGrossSalesOfGA101ToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne biib false credit duration Threshold of gross sales of GA 101 to be achieved in any 12 consecutive months under option one. false false false false false false false false false false false verboselabel false 1 false true false false 150000000 150.0 false false false xbrli:monetaryItemType monetary Threshold of gross sales of GA 101 to be achieved in any 12 consecutive months under option one. No authoritative reference available. false 23 Threshold of gross sales of GA 101 to be achieved in any 12 consecutive months under option two 2 biib_ThresholdOfGrossSalesOfGA101ToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionTwo biib false credit duration Threshold of gross sales of GA 101 to be achieved in any 12 consecutive months under option two. false false false false false false false false false false false verboselabel false 1 false true false false 500000000 500.0 false false false xbrli:monetaryItemType monetary Threshold of gross sales of GA 101 to be achieved in any 12 consecutive months under option two. No authoritative reference available. false 24 Threshold of earlier of GA101 CLL trigger, the second GA101 CLL sales trigger, and gross sales of New Product to be achieved in any calender year under sub option one and two of option two 2 biib_ThresholdOfEarlierOfGA101CLLTriggerSecondGA101CLLSalesTriggerAndGrossSalesOfNewProductToBeAchievedInAnyCalenderYearUnderSubOptionOneAndTwoOfOptionTwo biib false credit duration Threshold of earlier of GA101 CLL trigger, the second GA101 CLL sales trigger, and gross sales of New Product to be achieved... false false false false false false false false false false false verboselabel false 1 false true false false 150000000 150.0 false false false xbrli:monetaryItemType monetary Threshold of earlier of GA101 CLL trigger, the second GA101 CLL sales trigger, and gross sales of New Product to be achieved in any calender year under sub option one and two of option two. No authoritative reference available. false 25 Threshold of gross sales of New Product to be achieved in same calender year under sub option one and two of option two 2 biib_ThresholdOfGrossSalesOfNewProductToBeAchievedInSameCalenderYearUnderSubOptionOneAndTwoOfOptionTwo biib false credit duration Threshold of gross sales of New Product to be achieved in same calender year under sub option one and two of option two. false false false false false false false false false false false verboselabel false 1 false true false false 150000000 150.0 false false false xbrli:monetaryItemType monetary Threshold of gross sales of New Product to be achieved in same calender year under sub option one and two of option two. No authoritative reference available. false 26 Threshold of gross sales of new product to be achieved in any calender year under sub option three of option two 2 biib_ThresholdOfGrossSalesOfNewProductToBeAchievedInAnyCalenderYearUnderSubOptionThreeOfOptionTwo biib false credit duration Threshold of gross sales of new product to be achieved in any calender year under sub option three of option two. false false false false false false false false false false false verboselabel false 1 false true false false 350000000 350.0 false false false xbrli:monetaryItemType monetary Threshold of gross sales of new product to be achieved in any calender year under sub option three of option two. No authoritative reference available. false 28 RITUXAN [Member] | First Non-CLL GA 101 FDA Approval Occurs First [Member] | Before First New Product FDA Approval [Member] 0 na true na na No definition available. false true false false false false false false false false false http://biogenidec.com/role/collaborationsdetails false 1 false false false false 0 0 false false false false 2 true false false false RITUXAN [Member] biib_ProductsAxis xbrldi http://xbrl.org/2006/xbrldi biib_RITUXANMember biib_ProductsAxis explicitMember false false First Non-CLL GA 101 FDA Approval Occurs First [Member] us-gaap_ProductOrServiceAxis xbrldi http://xbrl.org/2006/xbrldi biib_FirstNonCLLGA101FDAApprovalOccursFirstMember us-gaap_ProductOrServiceAxis explicitMember false false Before First New Product FDA Approval [Member] biib_CollaborationsAxis xbrldi http://xbrl.org/2006/xbrldi biib_BeforeFirstNewProductApprovalMember biib_CollaborationsAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 na No definition available. No authoritative reference available. false 29 Co-promotion profit sharing formula 2 biib_CoPromotionProfitSharingFormulaAbstract biib false na duration Co-promotion Profit Sharing Formula Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Co-promotion Profit Sharing Formula Abstract. false 30 First $ 50.0 million 2 biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion biib false na instant Percentage of CoPromotion Operating Profits first fifty million. false false false false false false false false false false false verboselabel false 1 false true false false 0.3 0.3 false false false xbrli:pureItemType pure Percentage of CoPromotion Operating Profits first fifty million. No authoritative reference available. false 32 Until First GA 101 Threshold Date 2 biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne biib false na instant Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One. false false false false false false false false false false false verboselabel false 1 false true false false 0.39 0.39 false false false xbrli:pureItemType pure Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One. No authoritative reference available. false 33 After First GA 101 Threshold Date 2 biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract biib false na duration Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Abstract. false 37 Until Second GA 101 Threshold Date 2 biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSuboptionFour biib false na instant Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Suboption Four. false false false false false false false false false false false verboselabel false 1 false true false false 0.375 0.375 false false false xbrli:pureItemType pure Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Suboption Four. No authoritative reference available. false 38 After Second GA 101 Threshold Date 2 biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionThree biib false na instant Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Three. false false false false false false false false false false false verboselabel false 1 false true false false 0.35 0.35 false false false xbrli:pureItemType pure Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Three. No authoritative reference available. false 55 RITUXAN [Member] | GA 101 CLL Sales Trigger Occurs First [Member] | Before First New Product FDA Approval [Member] 0 na true na na No definition available. false true false false false false false false false false false http://biogenidec.com/role/collaborationsdetails false 1 false false false false 0 0 false false false false 3 true false false false RITUXAN [Member] biib_ProductsAxis xbrldi http://xbrl.org/2006/xbrldi biib_RITUXANMember biib_ProductsAxis explicitMember false false GA 101 CLL Sales Trigger Occurs First [Member] us-gaap_ProductOrServiceAxis xbrldi http://xbrl.org/2006/xbrldi biib_GA101CLLSalesTriggerOccursFirstMember us-gaap_ProductOrServiceAxis explicitMember false false Before First New Product FDA Approval [Member] biib_CollaborationsAxis xbrldi http://xbrl.org/2006/xbrldi biib_BeforeFirstNewProductApprovalMember biib_CollaborationsAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 na No definition available. No authoritative reference available. false 56 Co-promotion profit sharing formula 2 biib_CoPromotionProfitSharingFormulaAbstract biib false na duration Co-promotion Profit Sharing Formula Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Co-promotion Profit Sharing Formula Abstract. false 57 First $ 50.0 million 2 biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion biib false na instant Percentage of CoPromotion Operating Profits first fifty million. false false false false false false false false false false false verboselabel false 1 false true false false 0.3 0.3 false false false xbrli:pureItemType pure Percentage of CoPromotion Operating Profits first fifty million. No authoritative reference available. false 58 Above $50.0 million 2 biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion biib false na instant Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million. false false false false false false false false false false false verboselabel false 1 false true false false 0.35 0.35 false false false xbrli:pureItemType pure Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million. No authoritative reference available. false 82 RITUXAN [Member] | GA101 [Member] 0 na true na na No definition available. false true false false false false false false false false false http://biogenidec.com/role/collaborationsdetails false 1 false false false false 0 0 false false false false 4 USD true false false false RITUXAN [Member] biib_ProductsAxis xbrldi http://xbrl.org/2006/xbrldi biib_RITUXANMember biib_ProductsAxis explicitMember false false GA101 [Member] us-gaap_ProductOrServiceAxis xbrldi http://xbrl.org/2006/xbrldi biib_ProductTwoMember us-gaap_ProductOrServiceAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ na No definition available. No authoritative reference available. false 93 Collaborations (Textuals) [Abstract] 2 biib_CollaborationsTextualsAbstract biib false na duration Collaborations Textuals Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Collaborations Textuals Abstract. false 108 GA101 CLL Sales Trigger - US GA101 gross sales threshold 2 biib_GA101CLLSalesTriggerUSGA101GrossSalesThreshold biib false credit duration GA101 CLL Sales Trigger - US GA101 gross sales threshold. false false false false false false false false false false false verboselabel false 1 false true false false 500000000 500.0 false false false xbrli:monetaryItemType monetary GA101 CLL Sales Trigger - US GA101 gross sales threshold. No authoritative reference available. false 109 RITUXAN [Member] | After First New Product FDA Approval [Member] 0 na true na na No definition available. false true false false false false false false false false false http://biogenidec.com/role/collaborationsdetails false 1 false false false false 0 0 false false false false 5 true false false false RITUXAN [Member] biib_ProductsAxis xbrldi http://xbrl.org/2006/xbrldi biib_RITUXANMember biib_ProductsAxis explicitMember false false After First New Product FDA Approval [Member] biib_CollaborationsAxis xbrldi http://xbrl.org/2006/xbrldi biib_AfterFirstNewProductApprovalMember biib_CollaborationsAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 na No definition available. No authoritative reference available. false 110 Co-promotion profit sharing formula 2 biib_CoPromotionProfitSharingFormulaAbstract biib false na duration Co-promotion Profit Sharing Formula Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Co-promotion Profit Sharing Formula Abstract. false 111 First $ 50.0 million 2 biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion biib false na instant Percentage of CoPromotion Operating Profits first fifty million. false false false false false false false false false false false verboselabel false 1 false true false false 0.3 0.3 false false false xbrli:pureItemType pure Percentage of CoPromotion Operating Profits first fifty million. No authoritative reference available. false 113 Until First GA 101 Threshold Date 2 biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne biib false na instant Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One. false false false false false false false false false false false verboselabel false 1 false true false false 0.38 0.38 false false false xbrli:pureItemType pure Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One. No authoritative reference available. false 114 After First GA 101 Threshold Date 2 biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract biib false na duration Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Abstract. false 115 Until First Threshold Date 2 biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSuboptionOne biib false na instant Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Suboption One. false false false false false false false false false false false verboselabel false 1 false true false false 0.375 0.375 false false false xbrli:pureItemType pure Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Suboption One. No authoritative reference available. false 116 After First Threshold Date and until Second Threshold Date 2 biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSuboptionTwo biib false na instant Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Suboption Two. false false false false false false false false false false false verboselabel false 1 false true false false 0.35 0.35 false false false xbrli:pureItemType pure Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Suboption Two. No authoritative reference available. false 117 After Second Threshold Date 2 biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSuboptionThree biib false na instant Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Suboption Three. false false false false false false false false false false false verboselabel false 1 false true false false 0.3 0.3 false false false xbrli:pureItemType pure Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Suboption Three. No authoritative reference available. false 136 Ocrelizumab [member] | Maximum [Member] 0 na true na na No definition available. false true false false false false false false false false false http://biogenidec.com/role/collaborationsdetails false 1 false false false false 0 0 false false false false 6 true false false false Ocrelizumab [member] us-gaap_ProductOrServiceAxis xbrldi http://xbrl.org/2006/xbrldi biib_ProductOneMember us-gaap_ProductOrServiceAxis explicitMember false false Maximum [Member] biib_CollaborationsAxis xbrldi http://xbrl.org/2006/xbrldi biib_MaximumMember biib_CollaborationsAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 na No definition available. No authoritative reference available. false 147 Collaborations (Textuals) [Abstract] 2 biib_CollaborationsTextualsAbstract biib false na duration Collaborations Textuals Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Collaborations Textuals Abstract. false 148 Future royalties percentage to be received on sale of ocrelizumab 2 biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProductOne biib false na duration Future royalties percentage to be received on sale of product one. false false false false false false false false false false false verboselabel false 1 false true false false 0.24 0.24 false false false us-types:percentItemType pure Future royalties percentage to be received on sale of product one. No authoritative reference available. false 163 Ocrelizumab [member] | Minimum [Member] 0 na true na na No definition available. false true false false false false false false false false false http://biogenidec.com/role/collaborationsdetails false 1 false false false false 0 0 false false false false 7 true false false false Ocrelizumab [member] us-gaap_ProductOrServiceAxis xbrldi http://xbrl.org/2006/xbrldi biib_ProductOneMember us-gaap_ProductOrServiceAxis explicitMember false false Minimum [Member] biib_CollaborationsAxis xbrldi http://xbrl.org/2006/xbrldi biib_MinimumMember biib_CollaborationsAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 na No definition available. No authoritative reference available. false 174 Collaborations (Textuals) [Abstract] 2 biib_CollaborationsTextualsAbstract biib false na duration Collaborations Textuals Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Collaborations Textuals Abstract. false 175 Future royalties percentage to be received on sale of ocrelizumab 2 biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProductOne biib false na duration Future royalties percentage to be received on sale of product one. false false false false false false false false false false false verboselabel false 1 false true false false 0.135 0.135 false false false us-types:percentItemType pure Future royalties percentage to be received on sale of product one. No authoritative reference available. false 190 GA101 [Member] 0 na true na na No definition available. false true false false false false false false false false false http://biogenidec.com/role/collaborationsdetails false 1 false false false false 0 0 false false false false 8 USD true false false false GA101 [Member] us-gaap_ProductOrServiceAxis xbrldi http://xbrl.org/2006/xbrldi biib_ProductTwoMember us-gaap_ProductOrServiceAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 $ na No definition available. No authoritative reference available. false 201 Collaborations (Textuals) [Abstract] 2 biib_CollaborationsTextualsAbstract biib false na duration Collaborations Textuals Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Collaborations Textuals Abstract. false 203 Percentage of future development and commercialization expenses payable related to GA101 2 biib_PercentageOfFutureDevelopmentAndCommercializationExpensesPayableRelatedToGA101 biib false na duration Percentage of future development and commercialization expenses payable related to GA101. false false false false false false false false false false false verboselabel false 1 false true false false 0.35 0.35 false false false xbrli:pureItemType pure Percentage of future development and commercialization expenses payable related to GA101. No authoritative reference available. false 205 Sharing percentage of development expenses of GA101, prior to amendment 2 biib_SharingPercentageOfDevelopmentExpensesOfGA101PriorToAmendment biib false na duration Sharing percentage of development expenses of GA101, prior to amendment. false false false false false false false false false false false verboselabel false 1 false true false false 0.3 0.3 false false false xbrli:pureItemType pure Sharing percentage of development expenses of GA101, prior to amendment. No authoritative reference available. false 206 Compensation payment under terms of amendment for reimbursement of increased share of previously incurred expenses 2 biib_CompensationPaymentUnderTermsOfAmendmentForReimbursementOfIncreasedShareOfPreviouslyIncurredExpenses biib false debit duration Compensation payment under terms of amendment for reimbursement of increased share of previously incurred expenses. false false false false false false false false false false false verboselabel false 1 true true false false 10000000 10.0 false false false xbrli:monetaryItemType monetary Compensation payment under terms of amendment for reimbursement of increased share of previously incurred expenses. No authoritative reference available. false 217 GA101 [Member] | Maximum [Member] 0 na true na na No definition available. false true false false false false false false false false false http://biogenidec.com/role/collaborationsdetails false 1 false false false false 0 0 false false false false 9 true false false false GA101 [Member] us-gaap_ProductOrServiceAxis xbrldi http://xbrl.org/2006/xbrldi biib_ProductTwoMember us-gaap_ProductOrServiceAxis explicitMember false false Maximum [Member] biib_CollaborationsAxis xbrldi http://xbrl.org/2006/xbrldi biib_MaximumMember biib_CollaborationsAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 na No definition available. No authoritative reference available. false 228 Collaborations (Textuals) [Abstract] 2 biib_CollaborationsTextualsAbstract biib false na duration Collaborations Textuals Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Collaborations Textuals Abstract. false 231 Profit sharing on sale of GA101, percentage 2 biib_ProfitSharingOnSaleOfProductTwoPercentage biib false na duration Profit sharing on sale of product two, percentage. false false false false false false false false false false false verboselabel false 1 false true false false 0.39 0.39 false false false us-types:percentItemType pure Profit sharing on sale of product two, percentage. No authoritative reference available. false 244 GA101 [Member] | Minimum [Member] 0 na true na na No definition available. false true false false false false false false false false false http://biogenidec.com/role/collaborationsdetails false 1 false false false false 0 0 false false false false 10 true false false false GA101 [Member] us-gaap_ProductOrServiceAxis xbrldi http://xbrl.org/2006/xbrldi biib_ProductTwoMember us-gaap_ProductOrServiceAxis explicitMember false false Minimum [Member] biib_CollaborationsAxis xbrldi http://xbrl.org/2006/xbrldi biib_MinimumMember biib_CollaborationsAxis explicitMember Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 na No definition available. No authoritative reference available. false 255 Collaborations (Textuals) [Abstract] 2 biib_CollaborationsTextualsAbstract biib false na duration Collaborations Textuals Abstract. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false xbrli:stringItemType string Collaborations Textuals Abstract. false 258 Profit sharing on sale of GA101, percentage 2 biib_ProfitSharingOnSaleOfProductTwoPercentage biib false na duration Profit sharing on sale of product two, percentage. false false false false false false false false false false false verboselabel false 1 false true false false 0.35 0.35 false false false us-types:percentItemType pure Profit sharing on sale of product two, percentage. No authoritative reference available. false 1 50 false HundredThousands UnKnown UnKnown false true